Volume 37 Issue 3
May  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Nanjing University of traditional Chinese Medicine  > 2021  >  37(3): 419-427
LI Mei, CHEN Sheng-jun, WANG Xie-he, JIANG Zhong-hui, LI Ling-ling, XU Yi-liang, DI Liu-qing, GAO Zhu-ye. Study on Determination of Multi-Index Components and UPLC Fingerprint of Standard Decoction of Qingxin Jieyu Formula[J]. Journal of Nanjing University of traditional Chinese Medicine, 2021, 37(3): 419-427. doi: 10.14148/j.issn.1672-0482.2021.0419
Citation: LI Mei, CHEN Sheng-jun, WANG Xie-he, JIANG Zhong-hui, LI Ling-ling, XU Yi-liang, DI Liu-qing, GAO Zhu-ye. Study on Determination of Multi-Index Components and UPLC Fingerprint of Standard Decoction of Qingxin Jieyu Formula[J]. Journal of Nanjing University of traditional Chinese Medicine, 2021, 37(3): 419-427. doi: 10.14148/j.issn.1672-0482.2021.0419
shu

Study on Determination of Multi-Index Components and UPLC Fingerprint of Standard Decoction of Qingxin Jieyu Formula

doi: 10.14148/j.issn.1672-0482.2021.0419
  • 1.

    College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China

  • 2.

    Jiangyin Tianjiang Pharmaceutical Co., Ltd., Jiangyin, 214434, China

  • 3.

    Key Technology Laboratory for Preparation and Quality Control of Traditional Chinese Medicine Granules in Jiangsu, Jiangyin, 214434, China

  • 4.

    Jiangsu Traditional Chinese Medicine Formula Granule Engineering Center, Jiangyin, 214434, China

  • 5.

    Jiangsu Traditional Chinese Medicine Formula Granule Engineering Research Center, Jiangyin, 214434, China

  • 6.

    Xiyuan Hospital Affiliated to China Academy of Chinese Medical Science, Beijing, 100091, China

  • 7.

    Jiangsu Engineering Research Center for Efficient Delivery System of TCM, Nanjing, 210023, China

  • 8.

    National Center for Clinical Research on Cardiovascular Diseases of Chinese Medicine, Beijing, 100091, China

  • Received Date: 2021-01-13
    Available Online: 2021-12-21
  • Publish Date: 2021-05-10
    Abstract
  •   OBJECTIVE  To prepare 18 batches of standard decoction of Qingxin Jieyu Formula and study its substance benchmarks.   METHODS  The contents and transfer rates of salvianolic acid B, ferulic acid, total alkaloids, astragaloside Ⅳ, as well as extraction rate, oil content and fingerprint similarity of standard decoction were used as evaluation indexes to establish the allowable range of characterization parameters of standard decoction of Qingxin Jieyu Formula. The fingerprint similarity evaluation system software (2012 version) was used for fingerprint analysis, and cluster analysis (CA), principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) were used to evaluate the fingerprint common peak.   RESULTS  A total of 18 common peaks were determined, with the common peak similarity greater than 0.90. It was found that 18 batches of samples were grouped into two groups, and combined with the results of similarity, this difference may be related to the slices compatibility of different producing areas. According to the OPLS-DA VIP value combined with the load diagram, three peaks affecting the quality of the batch samples were selected, which were salvianolic acid B (peak 14), copithine hydrochloride (peak 10) and ferulic acid (peak 7) in turn. In order to reduce the quality difference between batches of samples and ensure the consistency of preparation quality, the medicinal materials from the same production area should be selected as far as possible in the subsequent preparation production.   CONCLUSION  The preparation method of standard decoction of Qingxin Jieyu Formula is stable, the multi-index content determination method is simple and fast, the fingerprint method is stable and the similarity is high, which can provide reference for the quality control of the subsequent preparation of Qingxin Jieyu Formula.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    卫生部国家中医药管理局关于印发医疗机构中药煎药室管理规范的通知[EB/OL]. (2009-03-27)[2021-01-13]http://yzs.satcm.gov.cn/gongzuodongtai/2018-03-25/6577.html.
    [2]
    杨立伟, 王海南, 耿莲, 等. 基于标准汤剂的中药整体质量控制模式探讨[J]. 中国实验方剂学杂志, 2018, 24(8): 1-6. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201808001.htm
    [3]
    陈士林, 刘安, 李琦, 等. 中药饮片标准汤剂研究策略[J]. 中国中药杂志, 2016, 41(8): 1367-1375. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZY201608001.htm
    [4]
    赵福丽. "愈梗通瘀汤精简方"对稳定型冠心病患者心血管事件的影响[D]. 济南: 山东中医药大学, 2018.
    [5]
    高翔. 清心解瘀方干预炎症反应增强的稳定性冠心病患者临床研究[D]. 北京: 中国中医科学院, 2017.
    [6]
    周湘, 钟正龙, 王宇, 等. 清心解瘀方对稳定性冠心病疗效及相关指标的变化研究[J]. 中华中医药学刊, 2019, 37(12): 3065-3069. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS201912061.htm
    [7]
    王贞, 张志国, 张君. 清心解瘀方治疗稳定性冠心病疗效观察及对ANK1、CD40L的影响[J]. 新中医, 2020, 52(17): 51-54. https://www.cnki.com.cn/Article/CJFDTOTAL-REND202017016.htm
    [8]
    李金根. 清心解瘀方对稳定性冠心病临床终点事件影响的随机双盲对照研究[D]. 北京: 北京中医药大学, 2018.
    [9]
    魏微. "愈梗通瘀汤精简方"对稳定型冠心病患者中间终点的影响[D]. 济南: 山东中医药大学, 2018.
    [10]
    鞠建庆. 清心解瘀方调控巨噬细胞焦亡稳定动脉粥样硬化易损斑块的机制研究[D]. 北京: 北京中医药大学, 2019.
    [11]
    王安璐. 清心解瘀方重塑肠道菌群调节动脉粥样硬化脂质代谢作用及机制研究[D]. 北京: 北京中医药大学, 2019.
    [12]
    李国臣. 愈梗通瘀汤精简方对冠心病稳定期气虚血瘀证患者生存质量的影响[D]. 济南: 山东中医药大学, 2017.
    [13]
    周淑妮, 于颖. 清心解瘀方治疗冠心病心绞痛疗效观察及对患者心功能、CXC型趋化因子和外周血单核细胞Toll样受体/髓样分化因子88/核转录因子κB信号通路的影响[J]. 河北中医, 2020, 42(6): 853-857, 861. doi: 10.3969/j.issn.1002-2619.2020.06.011
    [14]
    国家药典委员会. 中华人民共和国药典: 一部[S]. 北京: 中国医药科技出版社, 2020.
    [15]
    李圣耀, 杨琳, 高铸烨, 等. 清心解瘀方组方中药入血成分的网络药理学分析[J]. 中国实验方剂学杂志, 2018, 24(5): 198-202. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201805034.htm
    [16]
    居来提·艾买提, 阿布都沙拉木·阿布都热衣木, 兰怡. 黄芪甲苷对小鼠缺血再灌注心肌细胞自噬及炎症反应的影响[J]. 中国临床药理学杂志, 2018, 34(17): 2097-2099. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201817017.htm
    [17]
    李璐, 习瑾昆, 朱莹, 等. 黄芪甲苷的临床应用及心肌保护研究进展[J]. 中国煤炭工业医学杂志, 2016, 19(8): 1249-1252. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMGY201608044.htm
    [18]
    夏杨, 张惠军, 聂亚莉. 丹酚酸B预处理对心肌缺血/再灌注损伤能量代谢的影响[J]. 药物评价研究, 2018, 41(12): 2210-2213. https://www.cnki.com.cn/Article/CJFDTOTAL-YWPJ201812014.htm
    [19]
    周丹, 田天, 舒庆, 等. 丹酚酸B对大鼠缺血心肌血管再生的促进作用[J]. 中草药, 2018, 49(21): 5166-5169. doi: 10.7501/j.issn.0253-2670.2018.21.031
    [20]
    赵润英, 郝伟, 孟祥军, 等. 阿魏酸川芎嗪对大鼠心肌缺血再灌注损伤的保护作用及分子机制研究[J]. 中国实验方剂学杂志, 2012, 18(19): 230-234. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201219065.htm
    [21]
    于丁, 李倩, 于永燕, 等. 小檗碱联合卡托普利预处理对心肌缺血再灌注损伤的保护作用[J]. 河北医药, 2011, 33(10): 1445-1447. doi: 10.3969/j.issn.1002-7386.2011.10.001
    [22]
    王迎超. 川芎内酯及其主要成分Z-藁本内酯抗动脉粥样硬化作用机制研究[D]. 杭州: 浙江大学, 2013.
    [23]
    张伟, 张娟娟, 郭庆丰, 等. 广藿香醇药理作用研究进展[J]. 中国实验方剂学杂志, 2020, 26(3): 213-221. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX202003029.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(10)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (180) PDF downloads(122) Cited by()
    Proportional views
    Related

    Copyright © Journal of Nanjing University of traditional Chinese Medicine

    Sponsored by：Nanjing University of traditional Chinese MedicineAddress：No.138 xianlin Avenue, Qixia District, Nanjing cityChina Pos：210023

    Tel：025-85811935Email：xb@njucm.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return